LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
Gh Research plc
Headquarters:
Dublin, Ireland
Website:
https://www.ghres.com/
Year Founded:
2018
Status:
Public
Industry Sector:
HealthTechnology
CEO:
Villy Valcheva, MD
Number Of Employees:
50
Enterprise Value:
$215,496,998
PE Ratio:
-12.15
Exchange/Ticker 1:
NASDAQ:GHRS
Exchange/Ticker 2:
N/A
Latest Market Cap:
$564,455,680
BioCentury
|
Feb 7, 2025
Finance
Strong demand for Sionna latest good sign for IPOs: Public Equity Report
Vertex competitor posts a first-day gain after an upsized offering; plus financings for Gh Research and Tectonic
Read More
BioCentury
|
Feb 6, 2025
Product Development
Cardiometabolic wins among highlights in BioCentury’s latest Clinical Report
Plus readouts from Allakos, Leap, Cargo and more
Read More
BioCentury
|
Nov 8, 2022
Emerging Company Profile
Lusaris: treating depression with a new version of an old psychotropic
RA Capital leads $60M series A for the company, which is using Catalent’s technology to deliver 5-MeO-DMT
Read More
BioCentury
|
Oct 21, 2021
Data Byte
Europe’s largest venture rounds of the year
Europe’s top 13 biotech venture financings this year have raked in a combined $2B
Read More
Items per page:
10
1 - 4 of 4
Help Center
Username
Request a Demo
Request Training
Ask a Question
Elevio by Dixa
Help